Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug

A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

Gordon L. Amidon, Hans Lennernäs, Vinod P. Shah et al. · Pharmaceutical Research · 1995 · 5.3K citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

Medicine, Genetics, Hematology +14

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew et al. · Blood · 2001 · 1.5K citations · Full text

Life Sciences, Genetics, Hematology +16

Acute Myeloid Leukemia

Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations

Medicine, Oncology, Radiation Oncology +14

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Hitoshi Kiyoi, Tomoki Naoe, Yasuyuki Nakano et al. · PubMed · 1999 · 765 citations

Medicine, Genetics, Oncology +16